People · Operator
Named in public records as an officer, director or promoter · active 2015–2015 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NephroGenex, Inc. | — | Pharmaceuticals | Series A | $6.5M | $170.3M | 2015 |
John Hamill at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Hamill on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard Markham | 1 | 3 |
| Eugen Steiner | 1 | 2 |
| PIERRE LEGAULT | 1 | 2 |
| Marco Taglietti | 1 | 2 |
| Robert Seltzer | 1 | 2 |
| Richard J. Markham | 1 | 2 |
| James Mitchum | 1 | 1 |
| J. Wesley Fox | 1 | 1 |
| Eugen R. Steiner | 1 | 1 |
| David R. Ramsay | 1 | 1 |
| Mark R. Leschly | 1 | 1 |
| Jaikrishna Patel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.